Connect with us

BioPharma

Ilustrato Pictures International Inc (OTCMKTS: ILUS) Big Reversal on Georgia Fire and Rescue Buy (Update on 6 Recent Acquisitions, Up List Plans & New $15 million Funding

Published

2 years ago

on

Ilustrato Pictures International Inc (OTCMKTS: ILUS) is making a powerful reversal northbound since a brief dip below a dime on Monday. The stock is on fire and under heavy accumulation trading over $15 million in dollar volume on Tuesday alone. Since ILUS began operating under new management in January 2021, the company made 3 acquisitions prior to December 2021. In its first 11 months of operations, ILUS generated $11 million, having achieved nearly 45% growth from the 3rd to the 4th quarter of 2021. ILUS has now acquired 6 companies and is currently completing the acquisition of a further 4 companies. From its completed and current round of acquisitions, ILUS expects to increase its 2022 revenue on a quarterly basis to a run rate of $40 to $55 million. Microcapdaily first reported on ILUS on August 15 as the stock was moving up off the $0.05 mark before it ran to $0.50. The timing on ILUS could not be better here. 

On Tuesday ILUS reported the acquisition of Georgia Fire and Rescue Supply which does about $3.5 million in annual revenues according to management. This was preceded by the acquisitions of Vira Drones, an Unmanned Aerial Vehicle (UAV) company based in Germany and Switzerland and acquired KurveXR from TakeLeap, a futuristic technology company which creates artificial intelligence and machine learning solutions. The Company is looking to acquire a global firefighting equipment company which has annual revenues in excess of $100 million forming part of ILUS’ NASDAQ up list plans. The Company recently signed three funding deals for a total of $15 million, putting the company in a strong cash position to execute its current plans and move on its next phase of opportunities. The current amount of ILUS outstanding shares is 1,263,530,699 and the company is currently in the process of reducing these outstanding shares by a further 180 million. This will be completed in the coming days and weeks by updating the previously announced cancellation of 40 million shares and moving 140 million of ILUS CEO Nicolas Link’s common shares to a preferred share category. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Ilustrato Pictures International Inc (OTCMKTS: ILUS) is a public M&A Investment company operating out of New York, London, and Dubai focused on adding shareholder value through innovation and growth. ILUS International’s vision has evolved in line with the needs of the technology and manufacturing sectors it has been involved in.  We focus primarily on innovative emergency services, life safety and related technologies such as emergency response vehicles, electric utility vehicles, specialist vehicle conversions, disruptive firefighting equipment, wearable technology and related software solutions. With a proven record of acquiring carefully selected businesses that are appropriate to our vision, ILUS aims to complete further acquisitions of companies which possess innovative and disruptive technology and already achieve annual revenue of $1-10 million. ILUS International has already completed multiple acquisitions and is completing new acquisitions each quarter. Each acquisition rapidly increases the global expansion and growth of the company. Our primary focus is to add shareholder value as we continue to acquire, develop and grow companies which transform their respective industries and the world we live in. 

Microcapdaily first reported on ILUS on August 15 when the stock was still in single digits under a dime and well before it ran to a high of $0.5099 stating at the time: “The management team’s modus operandi has been to continually prioritize profitable growth and cash liquidity in order to allow it to execute the deals on its radar. With a number of new acquisitions in the pipeline, including two Letters of Intent which have been signed, ILUS is in a strong position to complete its targeted deals. ILUS skyrocketed out of the triple zeroes in January of this year topping out at 0.1898 before a brief dip below the $0.05 mark. Now on the rise up after a significant reversal ILUS is making a powerful move to the upside with liquidity and momentum on its side.” 

In January the Company acquired Vira Drones, an Unmanned Aerial Vehicle (UAV) company based in Germany and Switzerland. Vira Drones develops and manufactures UAVs or Industrial Drones. This technology is a world first in that it delivers the unmanned capability of light helicopters, with competitors of the acquisition achieving pre-production valuations of over $1.2 billion. Vira Drones also creates industrial heavy drones (UAVs) for rescue and logistics. Through the company’s proprietary technology, its UAVs can carry loads of up to 1000kg for as long as two hours, making these UAVs a viable unmanned alternative to light helicopters and free of their limitations. The company is on track to become the world’s leading cargo and rescue drone manufacturer and plans to capture a significant share of the light helicopter market in the process. The Vira Drones product range currently consists of the Vira M250, M500 and M750 which have a payload of 250kg, 500kg and 750kg respectively. The Vira M250 has a flight time of up to 4 hours. The Vira M1000 is currently in testing and will be able to transport 1000kg for a flight time of up to 2 hours. Maximum speeds for the UAVs range from 125 to 150 km/h. Vira Drones will continue to be managed by the two company founders, Valeriy Gorshkov and Igor Maslov, who respectively will remain CEO and CTO of the company. The global light helicopter market is currently valued at $13 billion per annum. Within this, the market for light helicopters used for logistics and rescue is estimated to be between $2 and $3 billion.   

To Find out the inside Scoop on ILUS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ILUS

ILUS also acquired KurveXR from TakeLeap, a futuristic technology company which creates artificial intelligence and machine learning solutions. KurveXR is the profitable and valuable Virtual and Augmented Reality division of TakeLeap, which ILUS is acquiring. KurveXR is based out of Dubai, United Arab Emirates with a software development hub in Southeastern Europe. ILUS is acquiring a substantial wealth of software code and intellectual property. For example, KurveXR has already developed over 6,000 custom digital assets for its training software. Putting this into perspective, a single 3D digital asset can take up to 4 months to develop. ILUS expects to generate $25 million over the next 24 months through KurveXR’s profitable software licensing model, given that the company already has contracts in place in seven countries. KurveXR is already discussing several substantial contracts in Europe and Asia. ILUS is already focusing on expanding the agreed acquisition’s current customer base beyond the Middle East and Europe and will be opening an office for the company in Florida, USA early in the second quarter of 2022. ILUS will also be moving five key members of the KurveXR team to Florida from Dubai to ramp up its global expansion. hrough the acquisition of KurveXR, ILUS is expanding its reach into the Metaverse market which is growing at meteoric speed. Already valued at $500 billion, the global Metaverse market is currently expected to exceed $1 trillion by 2025.  

On February 15 ILUS announced it has acquired Georgia Fire and Rescue Supply. This is ILUS’ first distribution acquisition and it is key to the rollout of ILUS technology across North America, whilst adding significant technical expertise and consistent, profitable revenue to the company. Founded in 2003 and headquartered out of Canton, Georgia, Georgia Fire and Rescue Supply, LLC (Georgia Fire) is a renowned nationwide distributor of firefighting and emergency response equipment.  The company holds several exclusive Georgian distribution contracts for the sales and servicing of some of the world’s largest firefighting equipment brands, such as Holmatro, Innotex and Paratech. It also distributes a wide range of products across North America, including prominent global brands for firefighting and the wider public safety sector. Some of these include but are not limited to; wildland firefighting, technical rescue, hazardous materials, emergency response, law enforcement and even homeland security. The profitable company has zero debt and an annual turnover of $3.5 million.  Of great importance to ILUS is the acquisition’s extensively experienced 7-member sales team, all of whom are retained firefighters with a wealth of technical knowledge and a thorough understanding of how to penetrate the US market. Georgia Fire currently operates from its 6,000 square foot distribution warehouse, from which several vehicles operate for sales and servicing purposes across Georgia, Alabama and North-East Florida. Within the coming months, ILUS plans to move Georgia Fire into a 15,000 square foot distribution facility with a showroom and dedicated vehicle yard. Georgia Fire is a leading distributor of Holmatro hydraulic rescue equipment in the United States. The company has been selling and servicing the global brand for many years. Although Georgia Fire distributes a very broad product range, Holmatro has long been the mainstay of the company’s product portfolio. Holmatro is the world’s leading hydraulic rescue tools brand. It is widely used by fire and rescue services to extricate road accident victims and for several related rescue applications. 

  For More on ILUS Subscribe Right Now!

ILUS is making a powerful reversal northbound since a brief dip below a dime on Monday. The stock is on fire and under heavy accumulation trading over $15 million in dollar volume on Tuesday alone. Since ILUS began operating under new management in January 2021, the company made 3 acquisitions prior to December 2021. In its first 11 months of operations, ILUS generated $11 million, having achieved nearly 45% growth from the 3rd to the 4th quarter of 2021. ILUS has now acquired 6 companies and is currently completing the acquisition of a further 4 companies. From its completed and current round of acquisitions, ILUS expects to increase its 2022 revenue on a quarterly basis to a run rate of $40 to $55 million. Microcapdaily first reported on ILUS on August 15 as the stock was moving up off the $0.05 mark before it ran to $0.50. The timing on ILUS could not be better here. On Tuesday ILUS reported the acquisition of Georgia Fire and Rescue Supply which does about $3.5 million in annual revenues according to management. This was preceded by the acquisitions of Vira Drones, an Unmanned Aerial Vehicle (UAV) company based in Germany and Switzerland and acquired KurveXR from TakeLeap, a futuristic technology company which creates artificial intelligence and machine learning solutions. The Company is looking to acquire a global firefighting equipment company which has annual revenues in excess of $100 million forming part of ILUS’ NASDAQ up list plans. The Company recently signed three funding deals for a total of $15 million, putting the company in a strong cash position to execute its current plans and move on its next phase of opportunities. The current amount of ILUS outstanding shares is 1,263,530,699 and the company is currently in the process of reducing these outstanding shares by a further 180 million. This will be completed in the coming days and weeks by updating the previously announced cancellation of 40 million shares and moving 140 million of ILUS CEO Nicolas Link’s common shares to a preferred share category.  We will be updating on ILUS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ILUS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ILUS either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

5 days ago

on

September 19, 2023

By

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

2 weeks ago

on

September 13, 2023

By

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

2 weeks ago

on

September 12, 2023

By

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.